NewAmsterdam Pharma Company N.V. (NAMS)
NASDAQ: NAMS · Real-Time Price · USD
18.03
+0.21 (1.18%)
Nov 4, 2024, 4:00 PM EST - Market closed

NAMS Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021 FY 2020
Period Ending
Jun '24 Dec '23 Dec '22 Dec '21 Dec '20
Revenue
7.4214.09102.69--
Revenue Growth (YoY)
-32.30%-86.28%---
Gross Profit
7.4214.09102.69--
Selling, General & Admin
50.6437.6319.5161.38
Research & Development
165.47159.4286.7428.974.05
Operating Expenses
216.11197.06106.2534.985.43
Operating Income
-208.69-182.97-3.56-34.98-5.43
Interest Expense
---0.29-0.41-0.34
Interest & Investment Income
13.6811.28---
Currency Exchange Gain (Loss)
-1.355.06-9.751.710.02
Other Non Operating Income (Expenses)
---8-7.22-
EBT Excluding Unusual Items
-196.36-166.63-21.59-40.9-5.75
Other Unusual Items
-33.02-10.28-1.04-0.88-
Pretax Income
-229.38-176.91-22.63-41.79-5.75
Income Tax Expense
0.030.03---
Net Income
-229.4-176.94-22.63-41.79-5.75
Net Income to Common
-229.4-176.94-22.63-41.79-5.75
Shares Outstanding (Basic)
878219115
Shares Outstanding (Diluted)
878219115
Shares Change (YoY)
108.42%333.20%72.75%119.58%-
EPS (Basic)
-2.64-2.15-1.19-3.81-1.15
EPS (Diluted)
-2.64-2.15-1.19-3.81-1.15
Free Cash Flow
-189.24-141.2410.44-29.54-5.98
Free Cash Flow Per Share
-2.17-1.720.55-2.69-1.20
Gross Margin
100.00%100.00%100.00%--
Operating Margin
-2811.00%-1298.56%-3.46%--
Profit Margin
-3090.01%-1255.76%-22.04%--
Free Cash Flow Margin
-2548.99%-1002.43%10.17%--
EBITDA
-208.63-182.92-3.55-34.97-5.43
EBITDA Margin
---3.45%--
D&A For EBITDA
0.060.050.010.010
EBIT
-208.69-182.97-3.56-34.98-5.43
EBIT Margin
---3.46%--
Source: S&P Capital IQ. Standard template. Financial Sources.